Sparfosic acid (trisodium)

Sparfosic acid (trisodium)

• CAS Number: 70962-66-2
• UNSPSC Description: Sparfosic acid trisodium is a DNA antimetabolite agent and a potent inhibitor of aspartate transcarbamoyl transferase. Aspartate transcarbamoyl transferase catalyzes the second step of de novo pyrimidine biosynthesis. Sparfosic acid trisodium synergistically enhances the cytotoxicity of a combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN) against human colon cancer cell lines[1][2][3].
• Target Antigen: Apoptosis
• Type: Reference compound
• Related Pathways: Apoptosis
• Applications: Cancer-programmed cell death
• Field of Research: Cancer; Metabolic Disease
• Assay Protocol: https://www.medchemexpress.com/sparfosic-acid-trisodium.html
• Purity: 98.0
• Solubility: DMSO : 180 mg/mL (ultrasonic)|H2O : 250 mg/mL (ultrasonic)
• Smiles: O=C(O[Na])C[C@@H](C(O[Na])=O)NC(CP(O)(O[Na])=O)=O
• Molecular Weight: 321.06
• References & Citations: [1]Wang J, et al. Elevated cyclin A associated kinase activity promotes sensitivity of metastatic human cancer cells to DNA antimetabolite drug. Int J Oncol. 2015 Aug;47(2):782-90.|[2]Angela D. Morris, et al. A New, Efficient, Two Step Procedure for the Preparation of the Antineoplastic Agent Sparfosic Acid|[3]Johnson RK, et al. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase. Cancer Res. 1976;36(8):2720-2725.|[4]Wadler S, et al. Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma. Eur J Cancer. 1996;32A(7):1254-1256.bioRxiv. 2023 Aug 3.|Nat Commun. 2024 Feb 16;15(1):1442.
• Shipping Conditions: Dry Ice
• Storage Conditions: -80°C, protect from light, stored under nitrogen
• Clinical Information: No Development Reported